Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Short-term Investments: 2020-2025

Historic Short-term Investments for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to $20.2 million.

  • Silence Therapeutics' Short-term Investments was N/A to $20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year change of. This contributed to the annual value of $26.0 million for FY2024, which is 29.66% down from last year.
  • Silence Therapeutics' Short-term Investments amounted to $20.2 million in Q3 2025, which was down 72.16% from $72.4 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Short-term Investments ranged from a high of $72.4 million in Q2 2025 and a low of -$357,140 during Q1 2021.
  • For the 3-year period, Silence Therapeutics' Short-term Investments averaged around $45.4 million, with its median value being $37.0 million (2023).
  • Data for Silence Therapeutics' Short-term Investments shows a peak YoY increase of -29.66% (in 2024) and a maximum YoY decrease of 29.66% (in 2024) over the last 5 years.
  • Over the past 4 years, Silence Therapeutics' Short-term Investments (MRQ) stood at $2.1 million in 2021, then surged by 1,697.41% to $37.0 million in 2023, then fell by 29.66% to $26.0 million in 2024, then decreased by 22.47% to $20.2 million in 2025.
  • Its Short-term Investments was $20.2 million in Q3 2025, compared to $72.4 million in Q2 2025 and $71.6 million in Q1 2025.